TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive Center Core Grants Picture Less Bleak; Competing Renewals To Receive 50% Of Recommended Increases January 4, 1980
